Revolutionizing platform & ongoing pipeline

At SunVax, we are building the next generation of mRNA therapeutics by integrating proprietary delivery systems, self-amplifying mRNA (samRNA), and novel immunotherapy platforms into a unified technological ecosystem. Our approach addresses key limitations in current mRNA modalities-such as delivery specificity, expression potency, and durability-enabling transformative advances in immuno-oncology, infectious disease, and in vivo cell engineering.

Our LNP delivery platform is founded on a rational design and high-throughput screening strategy. We have designed over 1 million novel ionizable lipid structures, successfully synthesized/screened more than 60,000 candidates and identified thousand effective LNP formulations across in vitro and in vivo models. Our LNPs are tailored to match specific payload requirements, from standard mRNAs to large size self-amplifying mRNAs.

Our proprietary samRNA platform encodes a replicase, enabling intracellular amplification of the mRNA payload after delivery. This yields:

• Select lead formulations with enhanced integrity, stability, high encapsulation efficiency, and low toxicity
• Prolonged duration of expression, reducing dose frequency

CATP™ is a platform that combines LNP delivery, samRNA payloads, and a pseudovirus-based amplification cascade. This design amplifies therapeutic payloads in situ, increases over hundreds-fold expression to reduce dosage and frequencies of dosing broadening the mRNA applications, enhances immune priming, and can convert "cold" tumors into "hot" immune-responsive environments. 

CTSD™ is an advanced LNP-based delivery platform engineered for targeted mRNA delivery to specific cell types, such as human and mouse immune cells including T cells, CD4 T cells, CD8 T cells, NK cells, B cells, Monocytes/Macrophages, and other types of non-immune cells. By ensuring selective expression in the intended cell populations, CTSD™ maximizes therapeutic efficacy while minimizing systemic toxicity.  This platform substantially expends the therapeutic scope of mRNA, enabling off-shelf in vivo CAR (Chimeric antigen receptor) therapies and other mRNA-based treatments for cancers, autoimmune disorders, and a wide range of other diseases. 

TSD™ is a targeted delivery platform designed to direct mRNA therapeutics to specific tissues, such as the liver or lymphatic system. By enabling localized expression, TSD™ enhances therapeutic efficacy for liver-associated diseases and strengthens immune responses for vaccines targeting infectious diseases and cancer.